Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL

Refractory B Acute Lymphoblastic Leukaemia Clinical Trial

Official title: A Phase II/III Prospective, Open Label Study to Evaluate Safety and Efficacy of Intravenous Autologous CD19 CAR-T Cells for Relapsed/ Refractory B-Acute Lymphoblastic Leukaemia

Status Recruiting

Clinical Trial Summary

This is Phase II / III, Prospective, single arm, Open Label Study to Evaluate Safety and Efficacy of Intravenous Autologous CD19 CAR-T Cells for Relapsed / Refractory B-Acute Lymphoblastic Leukaemia

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Lymphoid
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Refractory B Acute Lymphoblastic Leukaemia
• Relapsed B Acute Lymphoblastic Leukaemia

• NCT number: NCT03937544
• Study type: Interventional
• Source: National University of Malaysia
• Contact: S Fadilah Abdul Wahid, MD, DrIntMed, PhD
• Phone: +60391456450
• Email: sfadilah@ppukm.ukm.edu.my
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: March 19, 2019
• Completion date: March 18, 2024